Homology model of the CB1 cannabinoid receptor:: Sites critical for nonclassical cannabinoid agonist interaction

被引:76
|
作者
Shim, JY [1 ]
Welsh, WJ
Howlett, AC
机构
[1] Univ S Carolina, Coll Pharm, Dept Basic Pharmaceut Sci, Columbia, SC 29208 USA
[2] Univ Med & Dent New Jersey, Robert Wood Johnson Med Sch, Dept Pharmacol, Piscataway, NJ 08854 USA
[3] N Carolina Cent Univ, JL Chambers Biomed Biotechnol Res Inst, Durham, NC 27707 USA
关键词
homology; cannabinoid receptor; cannabinoid agonist interaction; G-proteins; G-protein coupled receptors; neuronal functions; bovine rhodopsin; molecular docking;
D O I
10.1002/bip.10424
中图分类号
Q5 [生物化学]; Q7 [分子生物学];
学科分类号
071010 ; 081704 ;
摘要
Association of cannabimimetic compounds such as cannabinoids, aminoalkylindoles (AAIs), and arachidonylethanolamide (anandamide) with the brain cannabinoid (CB,) receptor activates G-proteins and relays signals to regulate neuronal functions. A CB, receptor homology model was constructed using the published x-ray crystal structure of bovine rhodopsin (Palczewski et al., Science, 2000, Vol. 289, pp. 739-745) in the conformation most likely to represent the "high-affinity " state for agonist binding to G-protein coupled receptors (GPCRs). A molecular docking approach that combined Monte Carlo and molecular dynamics simulations was used to identify the putative binding conformations of nonclassical cannabinoid agonists, including AC-bicyclic CP47497 and CP55940, and ACD-tricyclic CP55244. Placement of these ligands was based upon the assumption of a critical hydrogen bond between the A-ring 011 and the side chain N of Lys192 in transmembrane helix 3. We evaluated two alternative binding conformations, C3-in and C3-out, denoting the directionality of the ligand C3 side chain within the receptor with respect to the inside or the outside of the cell. Assuming both the C3-in or C3-out conformation, the calculated ligand-receptor binding energy (DeltaE(bind)) was correlated with the experimentally observed binding affinity (K-i) for a series of nonclassical cannabinoid agonists. The C3-in conformation was marginally better than the alternative C3-out conformation in predicting the rank order of the tested nonclassical cannabinoid analogs. Adopting the C3-in conformation due to the greater number of receptor interactions with known pharmacophoric elements of the ligand, key residues were identified comprising the presumed hydrophobic pocket that interacts with the C3 side chain of cannabinoid agonists. Key hydrogen bonds would form between both K3.28(192) and E(258) and the A-ring OH, and between Q(261) and the C-ring C-12 hydroxypropyl. In summary, the present study represents one of the first attempts to construct a homology model of the CB1 cannabinoid receptor based upon the published bovine rhodopsin x-ray crystal structure and to elucidate the putative ligand binding site for nonclassical cannabinoid agonists. We postulated sites of the CB1 receptor critical for the ligand interaction, including the hydrophobic pocket interacting with the key pharmacophoric moiety, the C3 side chain. More work is needed to delineate between two alternative (and possibly other) binding conformations of the nonclassical cannabinoid ligands within the CB1 receptor. The present study provides a consistent framework for further investigation of the CB1 receptor-ligand interaction and for the study of CB1 receptor activation. (C) 2003 Wiley Periodicals, Inc.
引用
收藏
页码:169 / 189
页数:21
相关论文
共 50 条
  • [1] Homology Modeling and Docking Studies of Cannabinoid Receptor CB1
    Tu Guogang
    Li Shaohua
    [J]. ACTA CHIMICA SINICA, 2011, 69 (08) : 1007 - 1010
  • [2] The CB1 cannabinoid receptor is the major cannabinoid receptor at excitatory presynaptic sites in the hippocampus and cerebellum
    Kawamura, Y
    Fukaya, M
    Maejima, T
    Yoshida, T
    Miura, E
    Watanabe, M
    Ohno-Shosaku, T
    Kano, M
    [J]. JOURNAL OF NEUROSCIENCE, 2006, 26 (11): : 2991 - 3001
  • [3] Cannabinoid CB1 Receptor Antagonists
    Thomas, Brian F.
    [J]. DRUG DEVELOPMENT RESEARCH, 2009, 70 (08) : 525 - 526
  • [4] The CB1 cannabinoid receptor in the brain
    Howlett, AC
    [J]. NEUROBIOLOGY OF DISEASE, 1998, 5 (06) : 405 - 416
  • [5] CB1 cannabinoid receptor antagonists
    Barth, F
    [J]. ANNUAL REPORTS IN MEDICINAL CHEMISTRY, VOL 40, 2005, 40 : 103 - 118
  • [6] CB1 cannabinoid receptor ligands
    Thakur, GA
    Nikas, SP
    Makriyannis, A
    [J]. MINI-REVIEWS IN MEDICINAL CHEMISTRY, 2005, 5 (07) : 631 - 640
  • [7] The Cannabinoid CB1 Receptor in Schizophrenia
    Borgan, Faith
    Kokkinou, Michelle
    Howes, Oliver
    [J]. BIOLOGICAL PSYCHIATRY-COGNITIVE NEUROSCIENCE AND NEUROIMAGING, 2021, 6 (06) : 646 - 659
  • [8] Exploring determinants of agonist efficacy at the CB1 cannabinoid receptor: Analogues of the synthetic cannabinoid receptor agonist EG-018
    Finlay, David B.
    Thuy Nguyen
    Gamage, Thomas F.
    Chen, Shuli
    Barrus, Daniel G.
    Patel, Purvi R.
    Thomas, Brian F.
    Wiley, Jenny L.
    Zhang, Yanan
    Glass, Michelle
    [J]. PHARMACOLOGY RESEARCH & PERSPECTIVES, 2022, 10 (01):
  • [9] Ligand-specific homology modeling of human cannabinoid (CB1) receptor
    Ai, Rizi
    Chang, Chia-en A.
    [J]. JOURNAL OF MOLECULAR GRAPHICS & MODELLING, 2012, 38 : 155 - 164
  • [10] Hemopressin is an inverse agonist of CB1 cannabinoid receptors
    Heimann, Andrea S.
    Gomes, Lvone
    Dale, Camila S.
    Pagano, Rosana L.
    Gupta, Achla
    de Souza, Laura L.
    Luchessi, Augusto D.
    Castro, Leandro M.
    Giorgi, Renata
    Rioli, Vanessa
    Ferro, Elmer S.
    Devi, Lakshmi A.
    [J]. PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA, 2007, 104 (51) : 20588 - 20593